Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282025406> ?p ?o ?g. }
Showing items 1 to 96 of
96
with 100 items per page.
- W4282025406 endingPage "9569" @default.
- W4282025406 startingPage "9569" @default.
- W4282025406 abstract "9569 Background: Guidelines addressing melanoma in-transit metastasis (ITM) recommend immune checkpoint inhibitors (ICI) as a first-line treatment option, despite the fact that there are no efficacy data available from prospective trials for exclusively ITM disease. The aim of this study was to analyze the outcome of patients with ITM treated with ICI based on data from a large cohort of patients treated at international high‐volume melanoma centers. Methods: A multicenter retrospective cohort study of patients treated between January 2015 and December 2020 from Australia, Europe, and USA, evaluating treatment with ICI for ITM with or without nodal involvement (AJCC8 N1c, N2c and N3c) and without distant disease (M0). Patients were treated with PD-1 inhibitor (nivolumab or pembrolizumab) and/or CTLA-4 inhibitor (ipilimumab). We assessed response rates, progression-free survival (PFS), melanoma-specific survival (MSS) and overall survival (OS). Results: A total of 287 patients from 21 institutions in 8 countries were included. Immunotherapy was first-line treatment in 64 (22%) patients. Monotherapy with a PD-1 or CTLA-4 inhibitor was given in 233 (81%) and 23 (8%) patients respectively, while 31 (11%) received both in combination. Overall response rate was 56%, complete response (CR) rate 36% and progressive disease (PD) rate 32%. Median PFS was 10 months (95% CI 7.4-12.6 months) with a 1-, 2- and 5-year PFS rate of 48%, 33% and 18% respectively. Median MSS was not reached, and the 1-, 2- and 5-year MSS rates were 95%, 83% and 71% respectively. Conclusions: Systemic immunotherapy is an effective treatment for melanoma ITM. Future studies should evaluate the optimal role for systemic immunotherapy in the context of multimodality therapy including locoregional treatments such as surgery, intralesional therapy, and regional therapies." @default.
- W4282025406 created "2022-06-13" @default.
- W4282025406 creator A5002751837 @default.
- W4282025406 creator A5003126766 @default.
- W4282025406 creator A5003976494 @default.
- W4282025406 creator A5010897664 @default.
- W4282025406 creator A5019573174 @default.
- W4282025406 creator A5021981756 @default.
- W4282025406 creator A5026660064 @default.
- W4282025406 creator A5026967523 @default.
- W4282025406 creator A5029398339 @default.
- W4282025406 creator A5035929126 @default.
- W4282025406 creator A5036540296 @default.
- W4282025406 creator A5045165774 @default.
- W4282025406 creator A5052059834 @default.
- W4282025406 creator A5061810065 @default.
- W4282025406 creator A5062124149 @default.
- W4282025406 creator A5062156843 @default.
- W4282025406 creator A5070576000 @default.
- W4282025406 creator A5072207809 @default.
- W4282025406 creator A5083061830 @default.
- W4282025406 creator A5091523735 @default.
- W4282025406 date "2022-06-01" @default.
- W4282025406 modified "2023-10-01" @default.
- W4282025406 title "The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases: A multicenter cohort study." @default.
- W4282025406 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.9569" @default.
- W4282025406 hasPublicationYear "2022" @default.
- W4282025406 type Work @default.
- W4282025406 citedByCount "0" @default.
- W4282025406 crossrefType "journal-article" @default.
- W4282025406 hasAuthorship W4282025406A5002751837 @default.
- W4282025406 hasAuthorship W4282025406A5003126766 @default.
- W4282025406 hasAuthorship W4282025406A5003976494 @default.
- W4282025406 hasAuthorship W4282025406A5010897664 @default.
- W4282025406 hasAuthorship W4282025406A5019573174 @default.
- W4282025406 hasAuthorship W4282025406A5021981756 @default.
- W4282025406 hasAuthorship W4282025406A5026660064 @default.
- W4282025406 hasAuthorship W4282025406A5026967523 @default.
- W4282025406 hasAuthorship W4282025406A5029398339 @default.
- W4282025406 hasAuthorship W4282025406A5035929126 @default.
- W4282025406 hasAuthorship W4282025406A5036540296 @default.
- W4282025406 hasAuthorship W4282025406A5045165774 @default.
- W4282025406 hasAuthorship W4282025406A5052059834 @default.
- W4282025406 hasAuthorship W4282025406A5061810065 @default.
- W4282025406 hasAuthorship W4282025406A5062124149 @default.
- W4282025406 hasAuthorship W4282025406A5062156843 @default.
- W4282025406 hasAuthorship W4282025406A5070576000 @default.
- W4282025406 hasAuthorship W4282025406A5072207809 @default.
- W4282025406 hasAuthorship W4282025406A5083061830 @default.
- W4282025406 hasAuthorship W4282025406A5091523735 @default.
- W4282025406 hasConcept C121608353 @default.
- W4282025406 hasConcept C126322002 @default.
- W4282025406 hasConcept C141071460 @default.
- W4282025406 hasConcept C143998085 @default.
- W4282025406 hasConcept C167135981 @default.
- W4282025406 hasConcept C2777658100 @default.
- W4282025406 hasConcept C2777701055 @default.
- W4282025406 hasConcept C2780030458 @default.
- W4282025406 hasConcept C2780057760 @default.
- W4282025406 hasConcept C2781433595 @default.
- W4282025406 hasConcept C502942594 @default.
- W4282025406 hasConcept C71924100 @default.
- W4282025406 hasConcept C72563966 @default.
- W4282025406 hasConceptScore W4282025406C121608353 @default.
- W4282025406 hasConceptScore W4282025406C126322002 @default.
- W4282025406 hasConceptScore W4282025406C141071460 @default.
- W4282025406 hasConceptScore W4282025406C143998085 @default.
- W4282025406 hasConceptScore W4282025406C167135981 @default.
- W4282025406 hasConceptScore W4282025406C2777658100 @default.
- W4282025406 hasConceptScore W4282025406C2777701055 @default.
- W4282025406 hasConceptScore W4282025406C2780030458 @default.
- W4282025406 hasConceptScore W4282025406C2780057760 @default.
- W4282025406 hasConceptScore W4282025406C2781433595 @default.
- W4282025406 hasConceptScore W4282025406C502942594 @default.
- W4282025406 hasConceptScore W4282025406C71924100 @default.
- W4282025406 hasConceptScore W4282025406C72563966 @default.
- W4282025406 hasIssue "16_suppl" @default.
- W4282025406 hasLocation W42820254061 @default.
- W4282025406 hasOpenAccess W4282025406 @default.
- W4282025406 hasPrimaryLocation W42820254061 @default.
- W4282025406 hasRelatedWork W2155654588 @default.
- W4282025406 hasRelatedWork W2901619788 @default.
- W4282025406 hasRelatedWork W3055073804 @default.
- W4282025406 hasRelatedWork W3185931698 @default.
- W4282025406 hasRelatedWork W4221029189 @default.
- W4282025406 hasRelatedWork W4283523780 @default.
- W4282025406 hasRelatedWork W4288490070 @default.
- W4282025406 hasRelatedWork W4292373623 @default.
- W4282025406 hasRelatedWork W4295123368 @default.
- W4282025406 hasRelatedWork W4318473990 @default.
- W4282025406 hasVolume "40" @default.
- W4282025406 isParatext "false" @default.
- W4282025406 isRetracted "false" @default.
- W4282025406 workType "article" @default.